• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

受体酪氨酸激酶信号中的反馈和冗余:与癌症治疗的相关性。

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies.

机构信息

Division of Molecular Carcinogenesis and Cancer Genomics Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Division of Molecular Carcinogenesis and Cancer Genomics Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

出版信息

Trends Biochem Sci. 2014 Oct;39(10):465-74. doi: 10.1016/j.tibs.2014.08.010. Epub 2014 Sep 16.

DOI:10.1016/j.tibs.2014.08.010
PMID:25239057
Abstract

Mammalian cells have multiple regulatory mechanisms to deal with perturbations in cellular homeostasis, including feedback loops and crosstalk between the major signaling pathways. While these mechanisms are critically required to help cells survive under dynamic physiological circumstances, they also pose an impediment to the effective treatment of cancer. In this review, we describe what has been learned about interactions between receptor tyrosine kinase-dependent signaling pathways, and how this knowledge can be used to design rational and more effective combination therapies for cancer.

摘要

哺乳动物细胞有多种调节机制来应对细胞内稳态的紊乱,包括主要信号通路之间的反馈回路和串扰。虽然这些机制对于帮助细胞在动态生理环境中存活至关重要,但它们也给癌症的有效治疗带来了障碍。在这篇综述中,我们描述了受体酪氨酸激酶依赖性信号通路之间相互作用的研究进展,以及如何利用这些知识来设计合理且更有效的癌症联合治疗方案。

相似文献

1
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies.受体酪氨酸激酶信号中的反馈和冗余:与癌症治疗的相关性。
Trends Biochem Sci. 2014 Oct;39(10):465-74. doi: 10.1016/j.tibs.2014.08.010. Epub 2014 Sep 16.
2
Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. hedgehog 信号通路与其他信号通路的相互作用是癌症联合治疗的基础。
Cancer Treat Rev. 2014 Jul;40(6):750-9. doi: 10.1016/j.ctrv.2014.02.003. Epub 2014 Feb 24.
3
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.由于 Raf/MEK/ERK 和 PI3K/PTEN/Akt/mTOR 信号通路中的突变而导致的治疗抵抗。
J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647.
4
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.PI3K/AKT/mTOR 通路中癌症治疗的分子靶点。
Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9.
5
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.表皮生长因子受体抑制剂耐药的非小细胞肺癌治疗中 PI3K/Akt/mTOR 通路抑制剂的临床前原理。
Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16.
6
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.PI3K/AKT/mTOR 和 RAS/MEK/ERK 通路双重靶向策略治疗晚期癌症患者的临床疗效。
Clin Cancer Res. 2012 Apr 15;18(8):2316-25. doi: 10.1158/1078-0432.CCR-11-2381. Epub 2012 Jan 19.
7
Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs.基于荧光共振能量转移的表皮生长因子受体信号转导中前馈和反馈环的定量分析及其对分子靶向药物的敏感性。
FEBS J. 2014 Jul;281(14):3177-92. doi: 10.1111/febs.12852. Epub 2014 Jun 9.
8
Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.发现针对 PI3K/Akt/mTOR 通路的新型抗癌治疗药物。
Future Med Chem. 2009 Apr;1(1):137-55. doi: 10.4155/fmc.09.5.
9
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.针对乳腺癌治疗中的 PI3K/AKT/mTOR 和 Raf/MEK/ERK 通路。
Cancer Treat Rev. 2013 Dec;39(8):935-46. doi: 10.1016/j.ctrv.2013.03.009. Epub 2013 May 3.
10
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.抗癌治疗的新范式:用激酶抑制剂靶向多种信号通路。
Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005.

引用本文的文献

1
diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction Profiling.基于diaPASEF的化学蛋白质组学实现深度激酶组相互作用图谱分析。
J Proteome Res. 2025 Aug 27. doi: 10.1021/acs.jproteome.5c00109.
2
Synthesis and Antitumor Activity of 6-(2-Aminobenzo[]thiazol-5-yl) quinazolin-4(3)-one Derivatives.6-(2-氨基苯并噻唑-5-基)喹唑啉-4(3)-酮衍生物的合成及其抗肿瘤活性
ACS Omega. 2025 Feb 10;10(6):5686-5698. doi: 10.1021/acsomega.4c08645. eCollection 2025 Feb 18.
3
diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction Profiling.
基于diaPASEF的化学蛋白质组学实现深度激酶组相互作用谱分析。
bioRxiv. 2024 Nov 22:2024.11.22.624841. doi: 10.1101/2024.11.22.624841.
4
Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer.整合转录组分析确定吐根碱是克服肺癌对ALK抑制剂获得性耐药的一个有前景的候选药物。
Mol Oncol. 2025 Apr;19(4):1155-1169. doi: 10.1002/1878-0261.13738. Epub 2024 Nov 14.
5
Hexosaminidase B-driven cancer cell-macrophage co-dependency promotes glycolysis addiction and tumorigenesis in glioblastoma.己糖胺酶 B 驱动的癌细胞-巨噬细胞共生依赖性促进脑胶质瘤中的糖酵解成瘾和肿瘤发生。
Nat Commun. 2024 Oct 1;15(1):8506. doi: 10.1038/s41467-024-52888-0.
6
Innovative therapeutic strategies to overcome radioresistance in breast cancer.克服乳腺癌放射抗性的创新治疗策略。
Front Oncol. 2024 May 30;14:1379986. doi: 10.3389/fonc.2024.1379986. eCollection 2024.
7
Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.新型 RAF 靶向治疗方法克服当前临床限制,阻断 RAS/RAF 节点。
Mol Oncol. 2024 Jun;18(6):1355-1377. doi: 10.1002/1878-0261.13605. Epub 2024 Feb 16.
8
Large-scale comparison of machine learning methods for profiling prediction of kinase inhibitors.激酶抑制剂谱预测的机器学习方法大规模比较
J Cheminform. 2024 Jan 30;16(1):13. doi: 10.1186/s13321-023-00799-5.
9
Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy.靶向 RON 激酶(MST1R)异构体可提高抗肿瘤疗效。
Cell Death Differ. 2023 Dec;30(12):2491-2507. doi: 10.1038/s41418-023-01235-9. Epub 2023 Nov 6.
10
Androgen receptor is a determinant of melanoma targeted drug resistance.雄激素受体是黑色素瘤靶向药物耐药的决定因素。
Nat Commun. 2023 Oct 14;14(1):6498. doi: 10.1038/s41467-023-42239-w.